



## ABIVAX announces its financial calendar for 2017

Paris, December 19th 2016 - ABIVAX (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today provides its planned financial calendar for 2017, which is set as follows:

Date	Announcement
Wednesday March 15, 2017	Publication of 2016 Financial Statements
Friday April 28, 2017	Publication and Release of the Annual Financial Report
Friday June 23, 2017	Annual Shareholders Meeting
Wednesday September 20, 2017	Publication of Financial Statements as of June 30, 2017
Friday September 29, 2017	Publication and Release of 2017 Half Year Report

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section ([www.abivax.com/en](http://www.abivax.com/en)).

### About ABIVAX ([www.abivax.com](http://www.abivax.com))

ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease. ABIVAX leverages three technology platforms for drug discovery: an anti-viral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase

II clinical trials for providing a functional cure for patients with HIV/AIDS. It is a first-in-class oral small anti-viral molecule which blocks HIV replication through a unique mechanism of action and also has a strong anti-inflammatory effect. In addition, ABIVAX is advancing a clinical stage immune enhancer as well as multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue), and several of these compounds are planned to enter clinical development within the next 18 months. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX).

More information on the company is available at [www.abivax.com](http://www.abivax.com).

Follow us on Twitter @ABIVAX\_

### Contacts

#### Finance

Alain Chevallier  
[Alain.chevallier@abivax.com](mailto:Alain.chevallier@abivax.com)  
+33 1 53 83 08 41

#### Communication Agency

**ALIZE RP**  
Caroline Carmagnol/Margaux Pronost  
[abivax@alizerp.com](mailto:abivax@alizerp.com)  
+33 6 64 18 99 59 / +33 1 44 54 36 65

#### LifeSci Advisors

Chris Maggos  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)  
+41 79 367 6254